Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries.


Journal

The European journal of health economics : HEPAC : health economics in prevention and care
ISSN: 1618-7601
Titre abrégé: Eur J Health Econ
Pays: Germany
ID NLM: 101134867

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 14 04 2019
accepted: 16 01 2020
pubmed: 7 2 2020
medline: 10 3 2021
entrez: 7 2 2020
Statut: ppublish

Résumé

A centralised approach to health technology assessment (HTA) may facilitate optimal use of HTA resources. A regional approach may increase the chances of local implementation of recommendations. This study aimed to compare assessment procedures in England (centralised HTA approach) with Spain (regional HTA approach) discussing key challenges and opportunities from both approaches. We compared technology assessments of anticancer medicines in the two jurisdictions from 2008 to 2015. To assess the implementation of HTA recommendations, we assessed trends in medicine usage using regression methods. We used IQVIA data, from 2011 to 2016, for a sample of 11 medicines. We used CatSalut data from Catalonia to assess the implementation of local recommendations. In England, 66 assessments were undertaken by the National Institute for Health and Care Excellence (NICE), using a standardised methodology. In Spain, there were 79 reports undertaken by a range of bodies using a shared process and coordinated through the GENESIS collaboration; the assessment methods used varied substantially. Overall, the recommendations in the two jurisdictions were similar. Regression analyses indicate that where there is a positive recommendation by HTA bodies, the usage of the medicine responds most strongly (p < 0.001) in Catalonia (4.892), followed by England (3.120) and Spain (1.693). This study suggests that medicine utilisation does respond to the positive recommendations of HTA bodies. However, if HTA capacity is organised primarily regionally, considerable effort may be required in coordination, to ensure consistent and rigorous assessments and adequate implementation of HTA findings.

Identifiants

pubmed: 32026155
doi: 10.1007/s10198-020-01160-5
pii: 10.1007/s10198-020-01160-5
pmc: PMC7214388
doi:

Substances chimiques

Prescription Drugs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

621-634

Références

National Institute for Health and Care Excellence.: Guide to the Methods of Technology Appraisal. NICE, London (2013)
Guide to the processes of technology appraisal.: National Institute for Health and Care Excellence. https://www.nice.org.uk/process/pmg19/chapter/foreword (2014). Accessed 28 Nov 2018
McCabe, C., Culyer, A.J., Claxton, K.: The NICE cost-effectiveness threshold: what it is and what it means. Pharmacoeconomics 26(9), 733–744 (2008)
doi: 10.2165/00019053-200826090-00004
Rawlins, M.D., Culyer, A.J.: National Institute for clinical excellence and its value judgments. BMJ 329(7459), 224 (2004)
doi: 10.1136/bmj.329.7459.224
National Institute for Health and Care Excellence.: Interim Process and Methods of the Highly Specialised Technologies Programme. National Institute for Health and Care Excellence, London (2013)
PMG19 Addendum A: Final amendments to the NICE technology appraisal processes and methods guides to support the proposed new Cancer Drugs Fund arrangements. National Institute for Health and Care Excellence.  https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/process-and-methods-guide-addendum.pdf . Accessed 28 Nov 2018
Dillon, A., Landells, L.J.: NICE, the NHS, and cancer medicines. JAMA 319(8), 767–768 (2018)
doi: 10.1001/jama.2017.20552
Corbacho, B., Pinto-Prades, J.L.: Health economic decision-making: a comparison between UK and Spain. Br. Med. Bull. 103(1), 5–20 (2012)
doi: 10.1093/bmb/lds017
Antoñanzas, F.: The influence of economic evaluation studies on decision making in Spain. In: Eberhardt, S., Stoklossa, C., Graf von der Schulenburg, J.M. (eds). Euromet 2004: The Influence of Economic Evaluation Studies on Health Care Decision Making: A European Survey, vol. 52, pp. 179–192. IOS Press c2005, Health policy, Amsterdam, Washington, DC (2000)
López-Bastida, J., et al.: Spanish recommendations on economic evaluation of health technologies. Eur. J. Health Econ. 11(5), 513–520 (2010)
doi: 10.1007/s10198-010-0244-4
Pinto-Prades, J.L., Loomes, G., Brey, R.: Trying to estimate a monetary value for the QALY. J. Health Econ. 28(3), 553–562 (2009)
doi: 10.1016/j.jhealeco.2009.02.003
Vallejo-Torres, L., García-Lorenzo, B., Serrano-Aguilar, P.: Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 27(4), 746–761 (2018)
doi: 10.1002/hec.3633
Sampietro-Colom, L., et al.: History of health technology assessment: Spain. Int. J. Technol. Assess. Health Care 25(S1), 163–173 (2009)
doi: 10.1017/S026646230909059X
AETSA Report 3/2006. Update of the Guide for the Introduction of New Drugs. http://www.aetsa.org/download/publicaciones/antiguas/AETSA_2006_03_GINF_eng.pdf . Accessed 28 Nov 2018
http://catsalut.gencat.cat/ca/proveidors-professionals/farmacia-medicaments/programa-harmonitzacio-farmacoterapeutica/
Lozano-Blázquez, A., et al.: Differences in cancer drug assessment between Spain and the United Kingdom. Eur. J. Cancer 51(13), 1843–1852 (2015)
doi: 10.1016/j.ejca.2015.04.022
Prat, A., et al.: Letter to the editor regarding the paper by A. Lozano-Blázquez et al. Differences in cancer drug assessment between Spain and the United Kingdom. Eur.. J. Cancer 67, 55–56 (2016)
doi: 10.1016/j.ejca.2016.07.023
Drummond, M., et al.: A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France. Pharmacoeconomics 32(5), 509–520 (2014)
doi: 10.1007/s40273-014-0144-z
AETSA Report 1/2005. Cytostatic drugs usage in the treatment of patients with advanced cancer in Public Andalusian hospitals – primary research. http://www.aetsa.org/publicacion/utilizacion-de-citostaticos-en-cancer-avanzado-en-los-hospitales-del-sistema-sanitario-publico-de-andalucia-patrones-de-consumo-y-valoracion-economica-2000-2002/ . Accessed 28 Nov 2018
Rejón-Parrilla, J.C., et al.: The expanding value footprint of oncology treatments. Office of Health Economics, London (2014)
doi: 10.1016/j.jval.2014.08.2386
Richards, M., Extent and causes of international variations in drug usage: a report for the secretary of state for health. COI (2010)

Auteurs

B Corbacho (B)

York Trials Unit, ARRC Building, Department of Health Sciences, University of York, York, UK. belen.corbacho@york.ac.uk.

M Drummond (M)

Centre for Health Economics, University of York, York, UK.

R Santos (R)

Centre for Health Economics, University of York, York, UK.

E Jones (E)

Pope Woodhead, London, UK.

J M Borràs (JM)

Department Clinical Sciences, Universidad de Barcelona, Barcelona, Spain.

J Mestre-Ferrandiz (J)

Independent Economics Consultant, Madrid, Spain.

J Espín (J)

Escuela Andaluza de Salud Publica, Investigación Biosanitaria (ibs.GRANADA), Granada, Spain.
CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

N Henry (N)

CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
IQVIA, London, UK.

A Prat (A)

Pharmacy and Medicines Department, Servei Catala` de la Salut (CatSalut), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH